16 November 2015
Tragara Pharmaceuticals, Inc. (Tragara), a privately held clinical oncology company developing new treatments for cancer, announced today that China Oncology Focus Limited, an affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharma), has licensed Tragara's oral multi-kinase inhibitor, TG02. Lee’s Pharma, a public biopharmaceutical company listed on the main board of the Hong Kong Stock Exchange (stock code: 950), has an operating history of over 20 years in China's pharmaceutical industry.
First US Commercial Appointment - Atlas Genetics appoints Keith Stauffer as VP Sales & Marketing
16 November 2015
Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, today announces the appointment of Keith Stauffer as VP Sales and Marketing. Based in the newly opened Boston office, Keith will lead the launch and commercialisation of the Atlas Genetics io® System.
Analysts: Apple could turn to corporate markets to give Apple Watch a boost
16 November 2015
Apple has dealt with setbacks for its Apple Watch since rolling out the product earlier this year, shelving certain health features prior to launch and facing complaints over the accuracy of the device's heart rate monitor. With its med tech aspirations for the watch on the back burner, some analysts think the company could turn to corporate markets to boost sales for the product.
Germany, U.S. in hot pursuit of "messenger" drug molecules
16 November 2015
A molecule that carries the recipe for making drugs inside body cells is exciting scientists and investors alike, attracting hundreds of millions of dollars in a scramble for the next promising area of biotechnology.
China’s drug innovation – Is it at a tipping point?
16 November 2015
Chinese innovation has long been a fraught topic: Does China have it? If so, what is it? When will it be globally relevant? And, if you want to really get people going just ask if China can innovate at all. Some are optimistic that China is on the right path to become a true global innovation participant. McKinsey & Co. decided it was time to tackle this hot topic in its own fashion with a survey of industry leaders who have one foot in China and the other abroad.
13 November 2015
Epic Sciences, Inc. announced today a collaboration with the Abramson Cancer Center of the University of Pennsylvania (Penn) on multiple studies to explore biomarkers, identified by analysis of circulating tumor cells (CTCs) at a single cell resolution, that are predictive of response to personalized cancer therapeutics.
Science? Management? Indication? Why VCs might say no to your Deal
13 November 2015
Science or technology that fails to measure up and weak leadership make for sure-fire deal-killers in the venture capital (VC) world, but there’s more to it, said Jay Lichter, managing partner with Avalon Ventures in San Diego.
Pre-approval access: Walking a moral, ethical financial tightrope
13 November 2015
The needs of the many outweighing the needs of the one might seem the acme of logic, at least for a Vulcan. For humans, it's not so simple, and it's only one of several thorny problems industry, government and society must resolve to establish clear guidance to provide dying patients with compassionate use access to experimental drugs.
Stanford engineers develop touch-free ultrasound device for tumor detection
13 November 2015
As scientists search for lighter, low-cost alternatives to traditional imaging tools such as MRI or CT scans, engineers at Stanford University are developing a device that uses microwaves and ultrasound to pinpoint targets without touch, potentially improving tumor detection.
What's pharma got to say about pricing? PhRMA has some ideas
13 November 2015
As pricing issues continue to drag on pharma's reputation, the industry is finally pushing back hard, starting with the industry's lead trade association.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024